## GL: Globe Life Inc. - XLF: Financial Services

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.0% in lower entry zone (3.0-6.0%), top quartile (80th pct) cross-sectional ranking. Short-term MRS_5 (3.5%) confirms momentum alignment. Strong momentum (+6.7% 5-day acceleration). Outperforming sector by 2.2%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($133.94)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Globe Life (GL) Stock Trades Up, Here Is Why**
- Source: Finviz | 20251211T200840 | Bullish | Relevance: 100%
- Shares of Globe Life (GL) rose 2.7% after TD Cowen raised its price target on the stock and included it in its "Best Ideas 2026" list, citing the company's attractive and scalable business model. This recent jump follows a previous gain five months ago when the insurer beat earnings estimates and increased its full-year profit forecast. Globe Life is up 23.7% year-to-date and is trading near its 52-week high.

**2. Globe Life (GL) Stock Trades Up, Here Is Why**
- Source: The Globe and Mail | 20251211T200832 | Bullish | Relevance: 99%
-  Shares of Globe Life (NYSE:GL) rose 2.7% after TD Cowen increased its price target to $199 from $182, maintaining a "Buy" rating and adding the company to its "Best Ideas 2026" list. Analysts cited the insurer's "attractive, scalable business" which supports steady growth with lower risk. This positive analyst action follows Globe Life's strong second-quarter earnings beat and an increased full-year profit forecast issued five months prior.

**3. TD Cowen raises Globe Life stock price target to $199 on growth outlook**
- Source: Investing.com India | 20251211T162528 | Bullish | Relevance: 99%
-  TD Cowen has increased its price target for Globe Life (NYSE:GL) to $199, maintaining a Buy rating, due to the insurance company's "attractive, scalable business" and strong growth outlook. The firm included Globe Life in its "Best Ideas 2026" list, highlighting its consistent growth, low underwriting risk, and large addressable market in the underserved lower-middle and middle-income U.S. households. Despite trading at a discount compared to historical averages, the company boasts a perfect Piotroski Score of 9 and has paid dividends for 55 consecutive years, suggesting undervaluation relative to its growth prospects.

**4. Bronstein, Gewirtz & Grossman, LLC Encourages Globe Life Inc. (GL) Stockholders to Inquire about Securities Investigation**
- Source: FOX40 News | 20251209T160836 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globe Life Inc. (NYSE: GL) securities who bought shares before May 8, 2019, and still hold them. The investigation explores whether the company's officers and/or directors engaged in corporate wrongdoing. Investors are encouraged to visit the firm's website or contact them for more information, with representation on a contingency fee basis.

**5. Marshall Wace LLP Has $18.36 Million Stock Holdings in Globe Life Inc. $GL**
- Source: MarketBeat | 20251210T112129 | Somewhat-Bullish | Relevance: 98%
-  Marshall Wace LLP increased its stake in Globe Life Inc. by 38.0% in the second quarter, bringing its total holdings to 147,680 shares valued at $18.36 million. Other institutional investors like Norges Bank and Nuveen LLC also made significant changes to their positions in Globe Life. The company recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | TD Cowen | $199 | $182 | +9% |
| 2025-11-17 | Morgan Stanley | $177 | $179 | -1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | TD Cowen | main | Buy |
| 2025-11-17 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($5.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 12.6% (-2.7%)
- Blackrock Inc.: 7.2% (-2.1%)
- Invesco Ltd.: 4.8% (-1.9%)
- State Street Corpora: 4.1% (-3.5%)
- Wellington Managemen: 3.5% (-29.0%)

### Key Risks

1. Insider selling cluster: $5.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +6.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.68 elevated, pricing in significant growth expectations. Forward P/E 9.3x stretched relative to 3% growth. Quality metrics strong (ROE 22%, margin 19%). Balance sheet: strong liquidity (2.8x). Insider selling cluster ($5.4M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.3B |
| Beta | 0.48 |
| 52W Range | $103.71 - $147.83 |
| Short Interest | 2.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.68 |
| Forward P/E | 9.3 |
| Current P/E | 9.5 |
| YoY Growth | 2.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.7% to 4.0% (+6.7% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 80th percentile. MRS_5 at 3.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.66), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.99% (CS: 81) | Strong |
| RSI_14 | 67.1 | Neutral |
| MACD Histogram | 0.66 | Bullish |
| vs SMA20 | 1.047x | Above |
| vs SMA50 | 1.038x | Above |
| vs SMA200 | 1.071x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $139.04
- **Stop Loss:** $133.94 (3.7% risk)
- **Target:** $146.69 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 270
- **Position Value:** $37,540.80
- **Portfolio %:** 37.54%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-04 (Est: $3.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.54 | $4.81 | +5.9% |
| 2025Q2 | $3.25 | $3.27 | +0.8% |
| 2025Q1 | $3.24 | $3.07 | -5.2% |
| 2024Q4 | $3.12 | $3.14 | +0.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*